Fatigue, alopecia and stomatitis among patients with breast cancer receiving cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis

References

• Group EBCTC, (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687–1717.
   PubMed Web of Science ®Google Scholar
• Wilcken N, Hornbuckle J, Ghersi D, et al. Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer (review) chemotherapy alone versus endocrine therapy alone for metastatic breast cancer. Cochrane Database Syst Rev. 2003;(2):CD002747.
   Google Scholar
• Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16:25–35.
   PubMed Web of Science ®Google Scholar
• Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. [Internet]. 2016; NEJMoa1609709. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1609709.
   PubMed Web of Science ®Google Scholar
• Turner NC, Ro J, André F, et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med. [Internet]. 2015;1–11. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26030518.
   Google Scholar
• Verma S, Huang Bartlett C, Schnell P, et al. Palbociclib in combination with fulvestrant in women with hormone receptor-positive/HER2-negative advanced metastatic breast cancer: detailed safety analysis from a multicenter, randomized, placebo-controlled, phase III study (PALOMA-3). Oncologist. 2016;21(10):1–11.
   PubMed Web of Science ®Google Scholar
• Finn RS, Crown JP, Ettl J, et al. Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18. Breast Cancer Res. 2016;18:67.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.
   PubMed Web of Science ®Google Scholar
• Curigliano G, Gómez Pardo P, Meric-Bernstam F, et al. Ribociclib plus letrozole in early breast cancer: a presurgical, window-of-opportunity study. Breast. 2016;28:191–198.
   PubMed Web of Science ®Google Scholar
• Hurvitz S, Abad M, Rostorfer R, et al. Interim results from neomonarch: a neoadjuvant phase II study of abemaciclib in postmenopausal women with HR+/HER2- breast cancer (BC). ESMO 2016 proceeding, LBA 13. 2016.
   Google Scholar
• Saggar V, Wu S, Dickler MN, et al. Alopecia with endocrine therapies in patients with cancer. Oncologist. 2013;18:1126–1134.
   PubMed Web of Science ®Google Scholar
• Abrahams HJG, Gielissen MFM, Schmits IC, et al. Risk factors, prevalence, and course of severe fatigue after breast cancer treatment: a meta-analysis involving 12,327 breast cancer survivors. 2016;27(6):965–974.
   Google Scholar
• Saligan L, Olson K, Filler K, et al. The biology of cancer-related fatigue: a review of the literature. Support Care Cancer. 2015;23:2461–2478.
   PubMed Web of Science ®Google Scholar
• Rosman S. Cancer and stigma: experience of patients with chemotherapy-induced alopecia. Patient Educ Couns. 2004;52(3):333–339.
   PubMed Web of Science ®Google Scholar
• Browall M, Gaston-Johansson F, Danielson E. Postmenopausal women with breast cancer: their experiences of the chemotherapy treatment period. Cancer Nurs. 2006;29(1):34-42.
   Google Scholar
• Trüeb RM. Chemotherapy-induced alopecia. Semin Cutan Med Surg. 2009;28:11–14.
   PubMed Web of Science ®Google Scholar
• Services H. Common Terminology Criteria for Adverse Events v4.0 (CTCAE). Available from: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf. (v4.03: June 14, 2010).
   Google Scholar
• Sitzia J, Dikken C. Survey of the incidence and severity of side-effects reported by patients receiving six cycles of {FEC} chemotherapy. J Cancer Nurs. 1997;1:61–73.
   Google Scholar
• Land SR, Kopec JA, Yothers G, et al. Health-related quality of life in axillary node-negative, estrogen receptor-negative breast cancer patients undergoing AC versus CMF chemotherapy: findings from the national surgical adjuvant breast and bowel project B-23. Breast Cancer Res Treat. 2004;86:153–164.
   PubMed Web of Science ®Google Scholar
• Gallicchio L, Calhoun C, Helzlsouer KJ. Aromatase inhibitor therapy and hair loss among breast cancer survivors. Breast Cancer Res Treat. 2013;142:435–443.
   PubMed Web of Science ®Google Scholar
• Rugo HS, Hortobagyi GN, Yao J, et al. Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy. Ann Oncol. 2016;27(3):519-525.
   PubMed Web of Science ®Google Scholar
• Asghar U, Witkiewicz AK, Turner NC, et al. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov. 2015;14:130–146.
   PubMed Web of Science ®Google Scholar
• Fry DW, Harvey PJ, Keller PR, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther. 2004;3:1427–1438.
   PubMed Web of Science ®Google Scholar
• Clark AS, Karasic TB, DeMichele A, et al. Palbociclib (PD0332991)-a selective and potent cyclin-dependent kinase inhibitor: a review of pharmacodynamics and clinical development. JAMA Oncol. 2015;2:1–8.
   Web of Science ®Google Scholar
• Sledge GW, Toi M, Neven P, et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2? Advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017. JCO.2017.73.758. [Epub ahead of print].
   Web of Science ®Google Scholar
• Knudsen ES, Hutcheson J, Vail P, et al. Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature.Oncotarget. 2017;8(27):43678-43691.
   Google Scholar
• Finn R. PALOMA-2: addition of palbociclib to frontline letrozole significantly improves PFS in postmenopausal ER+/HER2- advanced breast cancer PALOMA 2 (Abstract 507). ASCO Annu. Meet. 2016;June.
   Google Scholar